Fate Therapeutics (FATE) Equity Ratio (2016 - 2025)
Fate Therapeutics' Equity Ratio history spans 14 years, with the latest figure at 0.65 for Q4 2025.
- For Q4 2025, Equity Ratio fell 10.18% year-over-year to 0.65; the TTM value through Dec 2025 reached 0.65, down 10.18%, while the annual FY2025 figure was 0.65, 10.18% down from the prior year.
- Equity Ratio reached 0.65 in Q4 2025 per FATE's latest filing, down from 0.68 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.76 in Q1 2023 to a low of 0.65 in Q4 2025.
- Average Equity Ratio over 5 years is 0.72, with a median of 0.73 recorded in 2021.
- Peak YoY movement for Equity Ratio: rose 19.28% in 2021, then fell 10.18% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.74 in 2021, then fell by 6.9% to 0.69 in 2022, then increased by 6.11% to 0.73 in 2023, then decreased by 0.62% to 0.72 in 2024, then dropped by 10.18% to 0.65 in 2025.
- Per Business Quant, the three most recent readings for FATE's Equity Ratio are 0.65 (Q4 2025), 0.68 (Q3 2025), and 0.7 (Q2 2025).